Premium
Androgen responsiveness of the new human endometrial cancer cell line MFE‐296
Author(s) -
Hackenberg Reinhard,
Beck Simone,
Filmer Angelika,
Nia Abdolhamid Hushmand,
Kunzmann Regina,
Koch Manuela,
Slater Emily P.,
Schulz KlausDieter
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910570121
Subject(s) - androgen receptor , androgen , biology , endocrinology , medicine , dihydrotestosterone , estrogen receptor , cell culture , receptor , cancer research , antiandrogen , prostate cancer , cancer , hormone , biochemistry , genetics , breast cancer
MFE‐296 endometrial cancer cells express androgen receptors in vitro. These cells, which are tumorigenic in nude mice, arc derived from a moderately differentiated human endometrial adenoeardnoma. They express vimentin and the cytokeratins 7, 8, 18, and 19. Karyotyping revealed near‐tetraploidy for most of the cells. No marker chromosomes were observed. DNA analyses confirmed the genetic identity of the cell line and the patient from whom the cell line was derived. Proliferation of MFE‐296 cells was inhibited by the progestin RS020 and the androgen dihydrotestosterone (DHT). The inhibition of proliferation by DHT was antagonized by the antiandrogen Casodex, demonstrating the involvement of the androgen receptor. Androgen binding was determined at 22,000 binding sites per cell using a whole‐cell assay (K D = 0.05 nM) and 30 fmol/mg protein with the dextran charcoal method; 7 fmol/mg protein of progesterone receptors were found, whereas estrogen receptors were below S fmol/mg protein. The androgen receptor was functionally intact, as demonstrated by transfection experiments with a reporter‐gene construct, containing an androgen‐responsive element. In MFE‐296 cells the content of the androgen receptor was up‐regulated by its own ligand. © Wiley‐Liss, Inc.